logo
  

Avanir Pharmaceuticals Inc. (AVNR) Has Jumped To A New High On Study Results

Avanir Pharmaceuticals Inc. (AVNR) announced positive results from its phase II clinical trial of AVP-923, for the treatment of agitation in patients with Alzheimer's disease, Monday morning.

Avanir Pharmaceuticals gapped open dramatically higher Monday and is now up 2.98 at $9.72 on above average volume. The stock has surged to a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Intelligent Investor.

First quarter growth data from China gained the maximum focus this week as trends in the massive emerging economy impact its trading partners. Elsewhere, the IMF released its latest global macroeconomic projections. Read our story to find out why comments from the Fed Chair Powell damped rate cut expectations. Meanwhile, there was some survey data that kindled hopes of a recovery in manufacturing. In the U.K., inflation data for March revealed some confusing trends.

View More Videos
Follow RTT